Want to see TSE:ACB full AI Analyst Report?
ACB Stock Chart & Stats
C$5.54
C$0.10(2.65%)
At close: 4:00 PM EDT
C$5.54
C$0.10(2.65%)
Day’s Range― - ―
52-Week RangeC$3.59 - C$9.33
Previous CloseN/A
Volume227.23K
Average Volume (3M)470.61K
Market Cap
C$389.05M
Enterprise ValueC$117.20
Total Cash (Recent Filing)C$149.12M
Total Debt (Recent Filing)C$22.68M
Price to Earnings (P/E)―
Beta1.53
Next Earnings
Nov 11, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.93
Shares Outstanding64,841,500
10 Day Avg. Volume315,064
30 Day Avg. Volume470,613
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.51
Price to Sales (P/S)0.81
P/FCF Ratio-7.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$5.65Price Target Upside1.99% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.42
Revenue Forecast (FY)C$293.75M
Bulls Say, Bears Say
Bulls Say
International Medical GrowthInternational medical growth and rising overseas revenue mix indicate Aurora is building a broader regulated-market platform rather than relying solely on Canada. Strong performance in Germany and Poland can support recurring demand, improve diversification, and provide a durable base for future expansion.
High Adjusted Gross MarginA 58% adjusted gross margin, supported by higher-margin international sales, demonstrates improving product and market economics. If Aurora sustains this mix, stronger gross profitability can provide funding for commercial expansion and help offset pressure from weaker lower-margin operations.
Strong Liquidity And Low LeverageNearly $150 million of liquidity with no debt gives Aurora meaningful financial flexibility and reduces refinancing risk. This balance-sheet position can support investments, acquisitions, and capacity expansion while providing resilience during the company’s transition toward profitable international growth.
Bears Say
Declining Revenue And Persistent LossesFalling trailing revenue alongside negative operating profit and net income shows that Aurora has not yet established durable earnings power. Volatile results increase uncertainty around the turnaround, while continued losses could constrain reinvestment and make future profitability dependent on successful execution.
Negative Free Cash FlowNegative operating and free cash flow means Aurora is consuming cash despite its strong balance sheet, limiting the durability of its current financial model. If cash burn persists, liquidity may increasingly be needed to fund operations, acquisitions, or capacity investments rather than growth alone.
Canadian Medical Reimbursement PressureA roughly 30% reimbursement reduction is a structural pressure on Canadian medical revenue and adjusted gross profit, not merely a temporary demand fluctuation. Lower reimbursement can compress economics in that market and increase Aurora’s reliance on international growth to sustain consolidated performance.
Aurora Cannabis News
ACB FAQ
What was Aurora Cannabis’s price range in the past 12 months?
Aurora Cannabis lowest stock price was C$3.59 and its highest was C$9.33 in the past 12 months.
What is Aurora Cannabis’s market cap?
Aurora Cannabis’s market cap is C$389.05M.
When is Aurora Cannabis’s upcoming earnings report date?
Aurora Cannabis’s upcoming earnings report date is Nov 11, 2026 which is in 48 days.
How were Aurora Cannabis’s earnings last quarter?
Aurora Cannabis released its earnings results on Aug 05, 2026. The company reported -C$0.07 earnings per share for the quarter, beating the consensus estimate of -C$0.183 by C$0.113.
Is Aurora Cannabis overvalued?
According to Wall Street analysts Aurora Cannabis’s price is currently Undervalued.
Does Aurora Cannabis pay dividends?
Aurora Cannabis does not currently pay dividends.
What is Aurora Cannabis’s EPS estimate?
Aurora Cannabis’s EPS estimate is -0.07.
How many shares outstanding does Aurora Cannabis have?
Aurora Cannabis has 64,841,500 shares outstanding.
What happened to Aurora Cannabis’s price movement after its last earnings report?
Aurora Cannabis reported an EPS of -C$0.07 in its last earnings report, beating expectations of -C$0.183. Following the earnings report the stock price went up 3.836%.
Which hedge fund is a major shareholder of Aurora Cannabis?
Currently, no hedge funds are holding shares in TSE:ACB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aurora Cannabis Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
C$5.65 (1.99% Upside)
C$5.65 (1.99% Upside)
Blogger Sentiment
Bullish
TSE:ACB Sentiment 88%
Sector Average 63%
Sector Average 63%
Insider Transactions
Sold Shares
Worth C$66.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.9%
Last 30 Days ▼ 4.1%
Last 30 Days ▼ 4.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-16.10%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-28.73%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Aurora Cannabis
Aurora Cannabis Inc. is a Canada-based firm specializing in the cultivation, processing, and global distribution of cannabis and its various derivative products. The company's operations encompass a broad spectrum of the cannabis industry, from facility engineering and design to genetic research, production, and the development of new products, all supported by extensive wholesale and retail networks. For medical users, Aurora offers diverse strains of dried cannabis, oils, capsules, and topical kits. Additionally, it markets a range of accessories, including vaporizers, consumable parts, herb mills (specifically for CanniMed products), grinders, and lockable vaporizer containers. The company is committed to advancing medical cannabis, with ongoing development across oral, topical, edible, and inhalable product categories. Aurora also provides key services such as patient counseling, design and construction assistance, and comprehensive analytical product testing for cannabis, alongside operating CanvasRX, a network dedicated to cannabis counseling and outreach. Its expansive brand family includes Aurora, Aurora Drift, San Rafael '71, Daily Special, AltaVie, MedReleaf, CanniMed, Whistler, Woodstock, and WMMC. The corporate headquarters are located in Edmonton, Canada.
ACB Company Deck
ACB Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a balanced picture: material short-term financial headwinds (notably a large year-over-year decline in adjusted EBITDA, lower adjusted net income, and negative free cash flow) driven largely by an external 30% reimbursement cut in Canadian medical. Offsetting these negatives are clear strategic strengths—17% international revenue growth to $43M, a 58% adjusted gross margin, strong cash position with no debt, an accretive EU GMP acquisition (Safari), genetics-driven production advantages (up to 40% yield improvement), and market leadership in several regulated international markets. Management frames FY2027 as a transitionary year with expected sequential improvement in Q2 and reiterated long-term targets (sustained double-digit growth and superior margins). Given the mix of significant near-term financial declines and pronounced strategic/operational positives, the overall tone is balanced.View all TSE:ACB earnings summariesACB Stock 12 Month Forecast
Average Price Target
C$5.65
▲(1.99% Upside)